1

Key Insights

2

Amyotrophic Lateral Sclerosis Market Overview at a Glance

2.1

Market Share (%) Distribution of Amyotrophic Lateral Sclerosis in 2017

2.2

Market Share (%) Distribution of Amyotrophic Lateral Sclerosis in 2026

3

Executive Summary of Amyotrophic Lateral Sclerosis

4

Amyotrophic Lateral Sclerosis: Disease Background and Overview

4.1

Introduction

4.2

Causes

4.3

Pathophysiology

4.4

Symptoms

4.5

Risk Factors

4.6

Diagnosis

5

Diagnostic Algorithm for Amyotrophic Lateral Sclerosis

6

Clinical Algorithm for Amyotrophic Lateral Sclerosis

7

Epidemiology and Patient Population

7.1

Key Findings

7.2

Total Prevalent Population of Amyotrophic Lateral Sclerosis

7.3

Total Diagnosed Prevalent Population of Amyotrophic Lateral Sclerosis

7.4

Type-specific Diagnosed Prevalent Population of Amyotrophic Lateral Sclerosis  

7.5

Age-specific Diagnosed Prevalent Population of Amyotrophic Lateral Sclerosis

7.6

Gender-specific Diagnosed Prevalent Population of Amyotrophic Lateral Sclerosis

8

Region Wise-Epidemiology of Amyotrophic Lateral Sclerosis

8.1

Assumptions and Rationale

8.2

North America

8.2.1

Assumptions and Rationale

8.2.2

Total Prevalent Population of Amyotrophic Lateral Sclerosis in the North America

8.2.3

Total Diagnosed Prevalent Population of Amyotrophic Lateral Sclerosis in the North America

8.2.4

Type-specific Diagnosed Prevalent Population of Amyotrophic Lateral Sclerosis in the North America

8.2.5

Age- specific Diagnosed Prevalent Population of Amyotrophic Lateral Sclerosis in the North America

8.2.6

Gender-specific Diagnosed Prevalent Population of Amyotrophic Lateral Sclerosis in the North America

8.3

Europe

8.3.1

Assumptions and Rationale

8.3.2

Total Prevalent Population of Amyotrophic Lateral Sclerosis in Europe

8.3.3

Total Diagnosed Prevalent Population of Amyotrophic Lateral Sclerosis in Europe

8.3.4

Type-specific Diagnosed Prevalent Population of Amyotrophic Lateral Sclerosis in Europe

8.3.5

Age- specific Diagnosed Prevalent Population of Amyotrophic Lateral Sclerosis in Europe

8.3.6

Gender-specific Diagnosed Prevalent Population of Amyotrophic Lateral Sclerosis in Europe

8.4

Asia-Pacific

8.4.1

Assumptions and Rationale

8.4.2

Total Prevalent Population of Amyotrophic Lateral Sclerosis in Asia-Pacific

8.4.3

Total Diagnosed Prevalent Population of Amyotrophic Lateral Sclerosis in Asia-Pacific

8.4.4

Type-specific Diagnosed Prevalent Population of Amyotrophic Lateral Sclerosis in Asia-Pacific

8.4.5

Age- specific Diagnosed Prevalent Population of Amyotrophic Lateral Sclerosis in Asia-Pacific

8.4.6

Gender-specific Diagnosed Prevalent Population of Amyotrophic Lateral Sclerosis in Asia-Pacific

8.5

Middle-East and Africa

8.5.1

Assumptions and Rationale

8.5.2

Total Prevalent Population of Amyotrophic Lateral Sclerosis in Middle-East and Africa

8.5.3

Total Diagnosed Prevalent Population of Amyotrophic Lateral Sclerosis in Middle-East and Africa

8.5.4

Type-specific Diagnosed Prevalent Population of Amyotrophic Lateral Sclerosis in Middle-East and Africa

8.5.5

Age- specific Diagnosed Prevalent Population of Amyotrophic Lateral Sclerosis in Middle-East and Africa

8.5.6

Gender-specific Diagnosed Prevalent Population of Amyotrophic Lateral Sclerosis in Middle-East and Africa

8.6

South America

8.6.1

Assumptions and Rationale

8.6.2

Total Prevalent Population of Amyotrophic Lateral Sclerosis in South America

8.6.3

Total Diagnosed Prevalent Population of Amyotrophic Lateral Sclerosis in South America

8.6.4

Type-specific Diagnosed Prevalent Population of Amyotrophic Lateral Sclerosis in South America

8.6.5

Age- specific Diagnosed Prevalent Population of Amyotrophic Lateral Sclerosis in South America

8.6.6

Gender-specific Diagnosed Prevalent Population of Amyotrophic Lateral Sclerosis in South America

9

Treatment

10

Treatment Algorithm (approaches for a particular disease) for Amyotrophic Lateral Sclerosis

11

Marketed drugs

11.1

Riluzole:  Covis Pharmaceuticals

11.1.1

Drug Description

11.1.2

Regulatory Milestones

11.1.3

Other Development Activities

11.1.4

Safety and Efficacy

11.1.5

Product profile

11.2

Tiglutik (Riluzole): ITF Pharma

11.2.1

Drug Description

11.2.2

Regulatory Milestones

11.2.3

Other Development Activities

11.2.4

Safety and Efficacy

11.2.5

Product profile

11.3

Radicava (Edaravone): Mitsubishi Tanabe Pharma

11.3.1

Drug Description

11.3.2

Regulatory Milestones

11.3.3

Other Development Activities

11.3.4

Safety and Efficacy

11.3.5

Product profile

Continued in the report...

12

Emerging Drugs

12.1

ODM-109: Orion

12.1.1

Product Description

12.1.2

Other Development Activities

12.1.3

Clinical Development

12.1.4

Clinical Trials Information

12.1.5

Safety and Efficacy

12.1.6

Product Profile

12.2

Arimoclomol: Orphazyme

12.2.1

Product Description

12.2.2

Other Development Activities

12.2.3

Clinical Development

12.2.4

Clinical Trials Information

12.2.5

Safety and Efficacy

12.2.6

Product Profile

12.3

Verdiperstat: Biohaven Pharmaceuticals

12.3.1

Product Description

12.3.2

Other Development Activities

12.3.3

Clinical Development

12.3.4

Clinical Trials Information

12.3.5

Safety and Efficacy

12.3.6

Product Profile

12.4.6

Product Profile

Continued in the report...

13

Amyotrophic Lateral Sclerosis: Regional Market Analysis

13.1

Key Findings

13.2

Market Size of Amyotrophic Lateral Sclerosis

14

The North America Market Outlook

14.1

North America Market Size

14.1.1

Total Market size of Amyotrophic Lateral Sclerosis

14.1.2

Market Size by Type

14.1.3

Market Size by Treatment type

14.1.4

Market Size by End users

15

Europe: Market Outlook

15.1

Europe Market Size

15.1.1

Total Market size of Amyotrophic Lateral Sclerosis

15.1.2

Market Size by Type

15.1.3

Market Size by Treatment type

15.1.4

Market Size by End users

16

Asia-Pacific Market Outlook

16.1

Asia-Pacific Market Size

16.1.1

Total Market size of Amyotrophic Lateral Sclerosis

16.1.2

Market Size by Type

16.1.3

Market Size by Treatment type

16.1.4

Market Size by End users

17

Middle-East and Africa Market Outlook

17.1

Middle-East and Africa Market Size

17.1.1

Total Market size of Amyotrophic Lateral Sclerosis

17.1.2

Market Size by Type

17.1.3

Market Size by Treatment type

17.1.4

Market Size by End users

18

South America Market Outlook

18.1

South America Market Size

18.1.1

Total Market size of Amyotrophic Lateral Sclerosis

18.1.2

Market Size by Type

18.1.3

Market Size by Treatment type

18.1.4

Market Size by End users

19

Market Drivers

20

Market Barriers

21

SWOT Analysis of Amyotrophic Lateral Sclerosis

22

Appendix

22.1

Report Methodology

23

About Report Ocean